Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma by Kim, Suzy et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 680708, 8 pages
doi:10.1155/2012/680708
Research Article
Efﬁcacyof Phosphatidylinositol-3Kinase Inhibitorsin a Primary
Mouse Model of UndifferentiatedPleomorphicSarcoma
Suzy Kim,1,2 Rebecca D. Dodd,1 JeffreyK.Mito,3 Yan Ma,1 Yongbaek Kim,4
Richard F. Riedel,5 andDavidG.Kirsch1,3
1Department of Radiation Oncology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA
2Department of Radiation Oncology, Boramae Hospital, Seoul National University Hospital, Seoul 156-707, Republic of Korea
3Department of Pharmacology and Cancer Biology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA
4Department of Clinical Pathology, College of Veterinary Medicine, Seoul National University, Seoul 156-707, Republic of Korea
5Division of Medical Oncology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA
Correspondence should be addressed to David G. Kirsch, david.kirsch@duke.edu
Received 4 January 2012; Revised 10 February 2012; Accepted 13 February 2012
Academic Editor: Luca Sangiorgi
Copyright © 2012 Suzy Kim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recent advances in sarcoma genomics have identiﬁed novel mutations in the PI3K pathway in human sarcomas. Here, we use a
mouse model of primary soft-tissue sarcoma for preclinical testing of doxorubicin and inhibitors of the PI3K pathway: BKM120
(PI3K inhibitor) and BEZ235 (a dual PI3K/mTOR inhibitor). Doxorubicin-treated tumors (n = 15) showed a partial response
rate of 6.6%, just as the majority of human sarcomas do not respond to doxorubicin. Treatment with BKM120 elicited a partial
response in 50% of tumors (n = 10), which was also seen in combination with doxorubicin (n = 10). Additionally, BKM120
treatment produced a robust delay in tumor growth kinetics. BEZ235-treated tumors (n = 9) showed a complete response rate of
11.1%. Combining BEZ235 with doxorubicin (n = 10) increased the complete response rate to 50% (P = 0.035). These studies
demonstrate that PI3K pathway inhibition is a viable and attractive target for soft-tissue sarcomas.
1.Introduction
Sarcomas are a rare, heterogeneous group of mesenchymal
neoplasms. Systemic chemotherapeutic options are limited
both in number and eﬃcacy for patients with advanced dis-
ease. Doxorubicin is currently one of the most commonly
used chemotherapeutic agents for patients [1]. Meta-analysis
of eight randomized, multicenter studies [2]h a se s t i m a t e d
response rates of 17–27% for single-agent doxorubicin (60–
80mg/m2). However, there is a severe risk of cardiac toxicity
associated with high cumulative doses of doxorubicin, in
addition to other side eﬀects including nausea, anemia, and
compromised immune function. Novel tumor-speciﬁc tar-
gets for chemotherapies would increase the available options
for sarcoma treatment and perhaps reduce the potential side
eﬀect proﬁle associated with current treatment approaches.
Genomic analyses of sarcomas with complex karyotypes
haverecentlyidentiﬁed novel mutations thatmay be targeted
by molecularly directed therapies [3]. One of the most
frequent somatic mutations is found in the PIK3CA gene,
which encodes the catalytic subunit of phosphatidylinositol-
3 kinase (PI3K). The PI3K pathway is commonly involved in
epithelial malignancies but has not been fully explored as a
target for sarcoma therapy. Initial studies showed that the
PI3K/mTOR inhibitor BEZ235 inhibited growth of Ewing’s
sarcoma and rhabdomyosarcoma xenografts [4]. However,
to the best of our knowledge, neither PI3K inhibitors nor
standard-of-care chemotherapies have been investigated in a
genetically engineered mouse model of soft-tissue sarcoma.
Inthisstudy,wetesttheeﬃcacyofdoxorubicinandtwoPI3K
inhibitors (BKM120 and BEZ235) in an immunocompetent
model of temporally—and spatially—restricted soft-tissue
sarcoma.
We have previously utilized the Cre-loxP system in mice
to activate conditional mutations in Kras and Trp53 (LSL-
KrasG12D;p 5 3 ﬂox/ﬂox) by intramuscular delivery of Cre re-
combinase to generate high-grade primary soft-tissue sar-
comas [5]. Cross-species genomic analysis revealed that this2 Sarcoma
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Figure 1: Mouse sarcoma cell line 4515 treated with BEZ235
and BKM120. Cells were treated with 500nM BEZ235 or 500nm
BKM120 for 18 hours. Western blot shows levels of total-S6 and
phospho-S6.
tumormodelmostcloselyresembleshumanundiﬀerentiated
pleomorphic sarcoma (UPS) [6]. Because this model is tem-
porally—and spatially—restricted, tumor size and response
to treatment can be easily monitored. Here, we use this
model to test the response of primary mouse sarcomas to
doxorubicin and to inhibition of the PI3K pathway with
BKM120 (PI3K inhibitor) and BEZ235 (dual inhibitor of
PI3K and mTOR), both provided by Novartis. Activation of
the PI3K pathway by growth signals initiates a signaling cas-
cade resulting in phosphorylation of AKT, activation of
mTOR, and subsequent phosphorylation of the ribosomal
subunit S6 [7]. Therefore, the juxtaposition of the pan-PI3K
inhibitor (BKM120) and the PI3K/mTOR dual inhibitor
(BEZ235) may reveal important information about the de-
sign of future molecularly targeted therapies for soft-tissue
sarcomas.
2. Results
2.1. Inhibition of PI3K and mTOR in BEZ235- and BKM120-
Treated Mouse Sarcoma Cell Lines. Before embarking on
in vivo screening of the compounds, we ﬁrst tested the agents
in vitro with cells derived from primary sarcomas in LSL-
KrasG12D;p 5 3 ﬂox/ﬂox mice. The sarcoma cells were treated
with either the dual PI3K/mTOR inhibitor BEZ235 or the
PI3K inhibitor BKM120 for 18 hours prior to harvest. The
BEZ235-treated cells exhibited decreased levels of phospho-
S6,amoleculedownstreamofthemTORpathway(Figure 1).
Additionally, the BKM120-treated cells demonstrated de-
creased levels of phospho-S6, showing the PI3K pathway
was inhibited through inhibition of this downstream target.
These data suggest that BEZ235 treatment in mouse sarcoma
cells eﬀectively inhibits targets of the mTOR pathway and
BKM120 treatment results in inhibition of PI3K pathway
targets.
2.2. Doxorubicin Treatment of Primary Sarcomas in Mice.
Doxorubicin is the most common standard-of-care chemo-
therapy for advanced stage sarcoma [1]. To model doxorubi-
cin therapy in a genetically engineered mouse model of
sarcoma, we used Cre-loxP technology to generate primary
high-grade soft-tissue sarcomas in mice. Tumors were ge-
nerated by intramuscular delivery of an adenovirus that
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Figure2:(a)Tumorvolumeofmicetreatedwithvehiclealone(red)
or doxorubicin alone (black). (b) Waterfall plot of tumor volume
response for vehicle (black bars) and doxorubicin (shaded bars).
Data is presented as percent maximal loss in tumor volume for
animals responding to treatment and as percent maximal gain in
tumor volume for nonresponders.
expresses Cre recombinase into compound mutant mice
with conditional mutations in both oncogenic Kras (LSL-
KrasG12D) and mutant Trp53 (p53ﬂox/ﬂox)[ 5]. Approximately
2-3 months later, these mice developed tumors resembling
human UPS/MFH (malignant ﬁbrous histiocytoma) at the
siteofinjection[6].Doxorubicintreatmentwasstartedwhen
thetumorvolumewasbetween150and300mm3,andtumor
v o l u m e sw e r em o n i t o r e d ,o na v e r a g e ,t w i c ew e e k l y .D a t aa r e
presented both as absolute tumor volume (Figure 2(a))a n d
in a waterfall plot that displays maximal percent change in
volume for each tumor following treatment (Figure 2(b)).
For the waterfall plots, tumors that responded to treatmentSarcoma 3
Table 1: Response rates of BKM120-treated tumors.
Tumor response rate
Complete Partial All responders
BKM120 0/10 5/10 5/10 (50%)
BKM120+Dox 0/10 6/10 6/10 (60%)
Total 0/20 11/20 11/20 (55%)
Table 2: Response rates of BKM120-treated tumors stratiﬁed by
initial tumor volume.
Initial tumor volume
P<0.05 Total
<250mm3 >250mm3
BKM120 tx:
complete
responders
0/14 0/6 no 0/20 (0%)
BKM120 tx: all
responders 8/14 3/6 no 11/20
(55%)
are shown as the greatest percent loss in tumor volume and
tumors with a maximal change of −100% represent tumors
that fully regressed and achieved a complete response. Tu-
mors that did not respond to treatment are shown as the
greatest percent gain in tumor volume during treatment.
Animals treated with vehicle alone showed no tumor re-
sponse (n = 0/6). In mice receiving an initial dose of doxo-
rubicin (10mg/kg), the growth of several tumors was de-
layed,althoughonly6.6%oftumorsshowedpartialresponse
to treatment (n = 1/15). This is similar to human sarcomas,
where the majority of patients with sarcomas do not show a
response to treatment with doxorubicin [2].
2.3. BKM120 Treatment of Primary Sarcomas in Mice. To test
the eﬀect of inhibiting the PI3K pathway in primary sarco-
masinvivo,weusedthenovelPI3Kinhibitor,BKM120.Mice
with tumors 150–300mm3 in volume were treated with
BKM120 (50mg/kg, administered 5 days/week) for 4–7
weeks. Treatment with either BKM120 or BKM120 with
doxorubicin delayed tumor growth in comparison to vehicle
alone(Figure 3,Table 1).Fiftypercentoftumorstreatedwith
BKM120 alone (n = 5/10) showed a partial tumor response.
The combination of BKM120 with doxorubicin had a partial
response rate of 60% (n = 6/10), which was similar to
BKM120 single-agent treatment (P = 0.343). Response rates
were not improved by beginning treatment on tumors at
volume less than 250mm3 instead of greater than 250mm3
(P = 0.076) (Table 2).
In addition to observing tumor response to treatment,
the time required for a tumor to triple in volume was cal-
culated (Figure 4). This measurement can determine diﬀer-
encesingrowthkineticsbetweengroupsthatachievedpartial
response to treatment [8]. Vehicle-treated tumors tripled in
size with an average 7.5 days (range 4–10 days), whereas do-
x o r u b i c i n - t r e a t e dt u m o r sr e q u i r e da na v e r a g eo f1 0 . 2d a y s
(range 6–30 days) to triple in volume (P = 0.31). Tumors
treated with BKM120 required 18.0 days (range 10–35 days)
t ot r i p l ei nv o l u m e( P = 0.0133, compared to vehicle alone).
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Figure 3: (a) Tumor volume of mice treated with BKM120 alone
(red)orBKM120+doxorubicin(black).Theaveragegrowthofvehi-
cle-treated tumors (blue) from Figure 2 is shown for comparison.
(b) Waterfall plot of tumor volume response for BKM120 (black
bars) and BKM120+doxorubicin (shaded bars). Data is presented
as percent maximal loss in tumor volume for animals responding to
treatment and as percent maximal gain in tumor volume for nonre-
sponders. Tumors that began treatment below 250mm3 are marked
with an asterisk (∗).
The combination of BKM120 with doxorubicin had the
greatest time to triple the tumor volume of 19.4 days (range
12–27 days), but this was not statistically diﬀerent than
BKM120 alone (P = 0.657).
2.4. BEZ235 Treatment of Primary Sarcomas in Mice. To test
the eﬀect of inhibiting both the PI3K and mTOR pathways
simultaneously with the BEZ235 inhibitor, tumor-bearing4 Sarcoma
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Figure 4: Time required for BKM120-treated tumors to triple
in volume. A paired Student’s t-test was performed. Groups
statistically diﬀe r e n tf r o mv e h i c l ea l o n ea r em a r k e dw i t ha n#( P<
0.05), and groups statistically diﬀerent from doxorubicin alone are
marked with an ∗ (P<0.05).
Table 3: Response rates of BEZ235-treated tumors.
Tumor response rate
Complete Partial All responders
BEZ235 1/9 2/9 3/9 (33%)
BEZ235+Dox 5/10 3/10 8/10 (80%)
Total 6/19 5/19 11/19 (58%)
Table 4: Response rates of BEZ235-treated tumors stratiﬁed by
initial tumor volume.
Initial tumor volume
P<0.05 Total
<250mm3 >250mm3
BEZ235 tx:
complete
responders
5/13 1/6 yes 6/19
(32%)
BEZ235 tx: all
responders 9/13 2/6 yes 11/19
(58%)
mice were treated with BEZ235 alone (50mg/kg, adminis-
tered 5 days/week) or a combination of doxorubicin and
BEZ235. Drug treatment began when tumor volumes reach-
ed 150–300mm3 and continued for 3-4 weeks. Tumor vol-
ume was measured twice weekly, on average. Tumor growth
was delayed in mice receiving BEZ235 or BEZ235 with dox-
orubicin in comparison to vehicle alone (Figure 5, Table 3).
Complete tumor response was observed in 11.1% of the
BEZ235-treated mice (n = 1/9), and 22.2% of tumors re-
sponded partially to treatment (n = 2/9). Interestingly,
combiningBEZ235withdoxorubicinresultedina50%com-
plete response rate (n = 5/10), much higher than that
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Figure 5: (a) Tumor volume of mice treated with BEZ235 alone
(red) or BEZ235+doxorubicin (black). The average growth of vehi-
cle-treated tumors (blue) from Figure 2 is shown for comparison.
(b) Waterfall plot of tumor volume response for BEZ235 (black
bars) and BEZ235+doxorubicin (shaded bars). Data is presented as
percent maximal loss in tumor volume for animals responding to
treatment and as percent maximal gain in tumor volume for nonre-
sponders. Tumors that began treatment below 250mm3 are marked
with an asterisk (∗).
observed for either treatment alone (P = 0.035). Addition-
ally,30%oftumorstreatedwiththeBEZ235anddoxorubicin
combination showed partial response (n = 3/10). In contrast
to results with BKM120, response rates were improved when
tumors were treated at volume of less than 250mm3 com-
pared to a volume greater than 250mm3 (P = 0.025)
(Table 4).Sarcoma 5
Table 5: Toxicity of BEZ235 and BKM120 scored by percent loss in
body weight.
Number of mice with maximal loss
in body weight
5–10% >10% # >15% Total
Doxorubicin
alone 0/8 (0%) 0/8 (0%) 0 0/8 (0%)
BEZ235+Dox 2/10 (20%) 5/10 (50%) 2 7/10
(70%)
BKM120 alone 3/10 (30%) 2/10 (20%) 0 5/10
(50%)
BKM120+Dox 2/9 (22%) 1/9 (11%) 1 3/9 (33%)
2.5. Toxicity of Treatment. During the experiments with
BEZ235, some mice died 6–8 days after drug administration.
To assess toxicity of BEZ235 or BKM120, we measured
the weight of mice with tumors treated with doxorubicin,
BKM120, or BKM120 and doxorubicin. We also assessed
weight loss in non-tumor-bearing, wild-type 129/SvJae mice
treated with BEZ235 and doxorubicin for 5 days per week for
two weeks. We recorded the percent change in body weight
twice weekly with a loss greater than 15% considered a ter-
minal endpoint (Supplementary Figure 1 in supplementary
Material available on line at doi:10.1155/2012/680708). With
this criterion, no toxicity was observed with doxorubicin
treatment alone (Table 5). In contrast, animals receiving the
combined BEZ235 and doxorubicin regimen showed sig-
niﬁcant weight loss, with 50% of animals losing >10% of
their body weight. BKM120-treated animals did not exhibit
such severe weight loss. Twenty percent of BKM120-treated
animals lost 10–15% of body weight, and no animal lost
greater than 15% of initial weight. Similar results were found
when BKM120 was combined with doxorubicin, with only 1
of 9 animals losing >10% of body weight.
3.MaterialsandMethods
3.1. Mouse Sarcoma Model. A l lm o u s ew o r kw a sp e r f o r m e d
in accordance with Duke University Institutional Animal
Care and Use Committee approved protocols. Tumors were
generated by injection of Adenovirus-expressing Cre re-
combinase (University of Iowa, Vector core) into the lower
left leg of p53ﬂox/ﬂox; LSL-KrasG12D compound mutant mice
as previously described [5]. After 2-3 months, tumors were
detected in the lower limb of animals. Tumor volumes were
calculated using the formula V = (π ×L×W ×H)/6, with L,
W,a n dH representing the length, width, and height of the
tumor in mm, respectively.
3.2. Doxorubicin and PI3K Inhibitor Treatment. Treatment
started when tumors were between 150 and 300mm3.M i c e
receiving vehicle alone were treated with NMP 10% (1-
methyl-2-pyrrolidone)/PEG300 90% (Fluka) orally 5 days
per week. Doxorubicin (Sigma) was dissolved in 2% DMSO
in PBS and injected intraperitoneally as a single bolus at
10mg/kg once on the ﬁrst day of the treatment. BEZ235
(Novartis) or BKM120 (Novartis) was dissolved in NMP
10% (1-methyl-2-pyrrolidone)/PEG300 90%. Mice were
treated with 50mg/kg of BEZ235 [4, 22] or BKM120 orally
5 days per week from the ﬁrst day of the treatment. Treat-
ment for all mice continued until tumors regressed or it
was necessary to sacriﬁce the mouse for animal welfare con-
cerns (i.e., animal was moribund; tumor volume reached
2000mm3; animal lost >15% body weight).
3.3. Tumor Growth Analysis. T u m o rr e s p o n s ei sd e ﬁ n e da s
any tumor volume that is less than baseline. A complete tu-
mor response is deﬁned as complete regression of a tumor so
that it is no longer palpable. For waterfall plot analyses, per-
cent maximal change is reported as the greatest percent loss
in tumor volume from baseline for tumors responding to
treatment. A value of −100% represents tumors that com-
pletely responded to treatment and were no longer detec-
table. Tumors that did not respond to treatment are shown
as the greatest percent gain in tumor volume from baseline
over the course of the treatment. Time required for tumors
to triple in volume was determined by reporting the day on
which a tumor volume reading exceeded three times the ini-
tial volume [8]. Mice excluded from this analysis includ-
ed animals that were sacriﬁced before the tumor could
triple in volume (1 BKM120-alone mouse and 1 BKM120/
doxorubicin mouse).
3.4. Statistical Analysis. Because the primary tumors were
treated across a span of several months, it was important to
verify that tumors were measured an equal number of times
across all treatment groups. Tumors were measured an aver-
age of 3.0 times during days 1–10 and an average of 2.2 times
during days 11–20. For days 1–10, and the vehicle-alone,
doxorubicin-alone, BKM120-alone, BKM120+doxorubicin,
BEZ235-alone, and BEZ2235+doxorubicin cohorts were
measured an average of 3.0, 2.9, 3.1, 3.2, 2.9, and 2.7 times,
respectively. For days 11–20, the vehicle-alone, doxorubicin-
alone, BKM120-alone, BKM120+doxorubicin, BEZ235-
alone, BEZ2235+doxorubicin cohorts were measured an
average of 2.2, 2.3, 2.6, 2.7, 2.2, and 1.0 times, respectively.
None of these measurement intervals were statistically diﬀer-
ent, with the exception of the BEZ235+doxorubicin tumors
during days 11–20 (P<0.001), which resulted from the loss
of mice during this time window. Graphs and statistics were
performed in Graph Pad 4.0. A paired, 2-tailed Student’s t-
test was performed to determine diﬀerences between treat-
ment groups.
3.5. Toxicity Studies. Healthy, wild-type 129S4/SvJae mice
were treated with BEZ235+doxorubicin for 5 days per week
for two weeks. Percent change in body weight was recorded
twice weekly, with a loss greater than 15% considered a ter-
minal endpoint. Tumor-bearing mice receiving treatment
with doxorubicin alone, BKM120 alone, or BKM120+doxo-
rubicin were also monitored for changes in body weight.
3.6. Western Blot Analysis. The mouse sarcoma cell line 4515
was derived from a primary sarcoma in a LSL-KrasG12D;
p53ﬂox/ﬂox mouse. The 4515 cells were cultured in DMEM +6 Sarcoma
10% FBS. They were treated with either BKM120 or BEZ235
(500nM) for 18 hours prior to harvest. Cells were washed
once with cold PBS (Sigma) and lysed for 10 minutes on ice
with RIPA buﬀer (Sigma), supplemented with phosphatase
inhibitors (Sigma, P5726 and P0044). Protein concentra-
tion was measured with BCA Protein Concentration Assay
(Thermo Scientiﬁc). MiniProtean TGX gels (BioRad) were
transferred to PVDF by wet transfer. Antibodies were from
Cell Signaling, including total S6 (no. 9202) and phospho-S6
(no. 5364).
4. Discussion
We have utilized a genetically engineered mouse model of
soft-tissue sarcoma to perform preclinical studies of doxo-
rubicin and PI3K pathway inhibitors. To our knowledge, this
is the ﬁrst study to use PI3K inhibitors and standard-of-care
chemotherapies in a primary mouse model of soft-tissue sar-
coma. We have assessed endpoints that are similar to those
used in human clinical trials, including complete and pa-
rtial response rates. We observed that treatment with stand-
ard-of-care doxorubicin produced a low response rate in a
genetically engineered mouse model of sarcoma. As the ma-
jority of human sarcomas do not respond to doxorubicin,
these results help credential the LSL-KrasG12D;p 5 3 ﬂox/ﬂox
mouse model for testing novel therapeutic agents. Treatment
with the PI3K inhibitor BKM120 showed a partial response
as a single agent and provided tumor-stabilizing eﬀects along
with greatly slowed tumor growth. This suggests that in-
hibition of PI3K alone is suﬃcient to see a robust delay in
tumor growth. Combining BKM120 with doxorubicin in-
creased beneﬁts, although these did not reach statistical sig-
niﬁcance. The average time to tumor tripling for BKM120
and doxorubicin was 1.4 days more than BKM120 alone,
which is similar to the 1.2-day increase for doxorubicin alone
compared to vehicle. This suggests that any interaction be-
tween BKM120 and doxorubicin is additive. However, it is
important to note that using the protocol of doxorubicin
administration in this study, neither the beneﬁts of doxoru-
bicin alone compared to vehicle nor doxorubicin addition to
BKM120treatmentwasstatisticallydiﬀerent.Treatmentwith
the dual PI3K/mTOR inhibitor BEZ235 produced a minimal
tumor response that increased dramatically when BEZ235
was combined with doxorubicin. However, severe toxicity
was observed in half of the animals given the combined
BEZ235/doxorubicin treatment. Of note, BKM120 alone or
BKM120/doxorubicin treatment was better tolerated than
BEZ235. The complete response observed with BEZ235, pa-
rticularly when combined with doxorubicin, suggests that
combining PI3K and mTOR inhibition may be a promising
therapy, but care must be taken to address safety and toxicity
concerns.Takentogether,thesepromising pre-clinicalresults
suggest that research exploring the potential beneﬁts of PI3K
inhibition in sarcoma patients is warranted.
Genetically engineered mouse models are vital tools for
cancer drug development [9], and they possess several ad-
vantages over traditionally used xenograft models. First,
these models recapitulate tumor-stroma interactions that are
fundamental to tumor growth and treatment response. This
point is especially salient when considering the contribution
of microenvironmental factors to overall tumor evolution,
including vasculature and immune cells. Second, the addi-
tionalheterogeneityfoundinprimarytumorsincomparison
to single-cell derived xenografts better models the genetic
diversity of human tumors that may inﬂuence response to
treatments. Indeed, several genetically engineered mouse
models are better predictors of therapeutic outcomes than
xenograft models [10]. For example, addition of erlotinib to
conventional chemotherapy showed no improvement in
progression-free survival for both a large patient cohort and
a Kras-mutant NSCLC mouse model; in contrast, xenograft
models suggested that erlotinib would increase eﬃcacy of
treatments in Kras-mutant NSCLC cell lines [10]. Third,
mouse models allow for studies that would be complex or
impossible to conduct during patient trials, such as stopping
responsive therapy to determine tumor control, testing com-
bination therapy for agents that are only in phase I develop-
ment, or modeling therapeutic resistance.
Results from studies in genetically engineered mouse
models can be further translated into clinical parameters by
calculatingendpointsthataresimilartothoseusedinhuman
clinical trials. Reporting values such as overall survival (OS)
and progression free survival (PFS) [10] for mouse studies
can allow direct comparison of data with large patient co-
horts. This information is important to determine if mouse
models respond similarly to standard-of-care chemother-
apies before they are used as platforms for screening novel
therapeutic agents. In the current study, we chose to report
the additional information of complete response rate and
partial response rate to treatment, in an attempt to extend
these observations towards clinical relevance. Indeed, this
measurement allows comparison of the low response rates to
doxorubicin treatment in both this mouse study and patient
reports. Observing tumor characteristics that are predictive
of outcomes in patient situations, such as tumor size at treat-
ment initiation, is another way that mouse studies can in-
form patient treatment. An interesting observation from our
study was the striking diﬀerence in tumor response based
on initial size of the treated tumors with BEZ235. This vol-
umetric response of tumors suggests this therapy may be
beneﬁcial in the adjuvant setting to treat minimal residual
disease. Additionally, our results suggest that clinical trials
for BEZ235 should evaluate whether tumor burden at the
beginning of treatment inﬂuences treatment response.
Although drug development in genetically engineered
mouse models is advantageous, there are several limitations
to these studies. Primarily, these models are unable to reﬂect
the vast genetic diversity found in human tumors. The mu-
tational heterogeneity of patient disease is one of the main
reasons clinical trials do not show the promising results
predicted from laboratory tests. Genotype-directed clinical
trials may improve upon these results. The LSL-KrasG12D;
p53ﬂox/ﬂox sarcomas are driven by overactive Kras, which
may increase sensitivity to PI3K inhibition. Therefore, these
results may only be applicable to patients with mutations in
PI3K-sensitive pathways.
PI3K inhibitors have shown eﬃcacy against a wide array
of cancers in a laboratory setting. BEZ235 decreased cellSarcoma 7
proliferation of breast cancer cell lines with PIK3CA muta-
tions [11] and cisplatin-resistant human ovarian cancer cells
[12]. Additionally, BEZ235 suppressed growth of xenograft
models of breast cancer [11], rhabdomyosarcoma [4], me-
tastatic melanoma [13], gastric cancer [14], hepatocellular
carcinoma [15], renal cell carcinoma [16], prostate cancer
[17, 18], primary eﬀusion lymphoma [19], glioma [18, 20],
and non-small-cell lung cancer [21]. BEZ235 has also shown
activity in genetically engineered mouse models, including
Kras-initiated ovarian carcinoma [12]. Alternatively, single-
agent BEZ235 therapy was not eﬀective in a primary NSCLC
mouse model, but combining BEZ235 with a MEK inhibitor
did inhibit tumor growth [22]. This suggests that PI3K-di-
rected drugs may be most eﬀective when combined with
other targeted therapies.
Molecularly targeted therapy against the PI3K pathway is
rapidly advancing into clinical use. BEZ235 is currently in
phase I/II clinical trials in patients with advanced solid tu-
mors, including advanced breast cancer. In this study, pat-
ients are prescreened for molecular alterations in PIK3CA
and/or PTEN. Such genotype-directed clinical trials may de-
termine if genetic mutations in the PI3K pathway contribute
to treatment response. According to http://clinicaltrials.gov/,
new BEZ235 trials are opening for patients with advanced
endometrial cancer and metastatic breast cancer. Several
Phase II trials for BKM120 are currently recruiting patients
with recurrent glioblastoma, metastatic renal cell carcinoma,
metastatic castration-resistant prostate cancer, metastatic
non-small-celllung cancer,andHER2-positive breastcancer.
Additional phase 1 studies are using alternative PI3K inhi-
bitorsincombinationwithotheragents,suchasstandard-of-
care chemotherapies, MEK inhibitors, or Bevacizumab. We
believe that the data presented in the paper suggests that
PI3K-directedtherapymaybebeneﬁcialforsarcomapatients
and should be further explored.
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